HealthRX vs Blue Haven RX
Two GLP-1 desks, one scoreboard. We put HealthRX and Blue Haven RX head-to-head on the published Brief Score — the same six factors, scored the same way.
HealthRX
The verdict
HealthRX takes this head-to-head.
HealthRX scores 86 to 55 on our six-factor Brief Score — A LegitScript-certified, physician-supervised desk (healthrx.com) whose real hook is breadth: injectable and a rare oral GLP tablet, on both molecules, with transparent no-insurance monthly pricing.
That doesn't make Blue Haven RX a bad call — it's best for people wanting flat all-inclusive compounded glp-1 pricing with no charge until a doctor approves. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| HealthRX | Blue Haven RX | |
|---|---|---|
| Brief Score | 86/100 (B) | 55/100 (C) |
| Semaglutide | $189/mo | From $179/mo (medication billed separately, compounded) |
| Tirzepatide | $349/mo | From $259/mo (medication billed separately, compounded) |
| Coverage | Not publicly listed | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.
Blue Haven RX: New to the tracker on 1 August 2026. The published line reads From $179/mo (medication billed separately, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.